-
Article
ZnS, CdS and ZnxCd1−xS Thin Films from Zn(II) and Cd(II) Complexes of 1, 1, 5, 5-Tetramethyl -2-4-dithiobiuret As Single Molecular Precursors
Synthesis of zinc and cadmium complexes of 1, 1, 5, 5-tetramethyl-2-4-dithiobiuret (M(N(SCNMe2)2)2) (M = Zn, Cd) is described together with X-ray single crystal of cadmium complex. These complexes have been used ...
-
Chapter
Selenium and Tellurium Containing Precursors for Semiconducting Materials
The preparation of thin films and/or small particles of metal selenides and tellurides is reviewed with particular emphasis on the use of single source precursors.
-
Article
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide
Treatment options are limited in myeloma relapsed or refractory to both bortezomib and lenalidomide (double-relapsed/refractory multiple myeloma; DRMM). Bendamustine is an antitumour agent that has efficacy in...
-
Article
Open AccessFlexible and High Performance Supercapacitors Based on NiCo2O4for Wide Temperature Range Applications
Binder free nanostructured NiCo2O4 were grown using a facile hydrothermal technique. X-ray diffraction patterns confirmed the phase purity of NiCo2O4. The surface morphology and microstructure of the NiCo2O4 anal...
-
Article
Self-assembly of P22 protein cages with polyamidoamine dendrimer and inorganic nanoparticles
Protein cage based nanoarchitectures hold great potential in the fields of energy, catalysis, and bio-applications owing to their ability to tune material’s properties in a benign biomimetic approach. We demon...
-
Article
Open AccessMultiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment
Interactions between multiple myeloma (MM) and bone marrow (BM) are well documented to support tumour growth, yet the cellular mechanisms underlying pain in MM are poorly understood. We have used in vivo murine m...
-
Article
Open AccessTranscriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease
Multiple myeloma is an incurable, bone marrow-dwelling malignancy that disrupts bone homeostasis causing skeletal damage and pain. Mechanisms underlying myeloma-induced bone destruction are poorly understood a...
-
Article
Open AccessDevelopments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
The evolving paradigm of continuous therapy and maintenance treatment approaches in multiple myeloma (MM) offers prolonged disease control and improved outcomes compared to traditional fixed-duration approache...
-
Article
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by ...
-
Article
Open AccessDeepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), wit...
-
Article
Open AccessOptimizing spectral quality with quantum dots to enhance crop yield in controlled environments
Bioregenerative life-support systems (BLSS) involving plants will be required to realize self-sustaining human settlements beyond Earth. To improve plant productivity in BLSS, the quality of the solar spectrum...
-
Article
Open AccessManagement of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life
Treatment options in multiple myeloma (MM) are increasing with the introduction of complex multi-novel-agent-based regimens investigated in randomized clinical trials. However, application in the real-world se...
-
Article
Open AccessA phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
-
Article
Open AccessOral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Multiple myeloma (MM) patients typically receive several lines of combination therapy and first-line treatment commonly includes lenalidomide. As patients age, they become less tolerant to treatment, requiring...
-
Article
Open AccessBortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
-
Article
Open AccessProlyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA sy...
-
Article
Open AccessCorrection: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
-
Article
Open AccessMonitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, ...
